$GKOS News

What Glaukos Doubters Missed

How Investors May Respond To Glaukos (GKOS) Positive Trial Results

Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup

BTIG Maintains Buy on Glaukos, Raises Price Target to $205

Glaukos: Steep Premium For New Therapies And Growth

Glaukos: The Second J-Code Rewrites The Risk Math

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating iDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority And Clinically Meaningful IOP Reduction Vs Cataract Surgery Alone

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Will Three-Year Epioxa Data in Keratoconus Shift Glaukos' (GKOS) Corneal Portfolio Narrative?

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific Biologic

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today

$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today

Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus

Glaukos (GKOS) Stock Looks Fully Priced Against Its Sales Growth Story

Glaukos (GKOS), Why Is It Back In The Spotlight?

If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today